Memorandum 2011-003 December 28, 2010

LIMITED SOURCES JUSTIFICATION ORDER >\$3,000 FAR PART 8.405-6

2237 Transaction # or Vista Equipment Transaction #:	
This acquisition is conducted under the authority of the service listed in par. 3 below is sole source, therefore, co FAR Subpart 8.4 – Federal Supply Schedules, is preclude	onsideration of the number of contractors required by
Restricted to the following source: Provide <u>original made</u> service. (If a sole source manufacturer distributes via de	
Manufacturer/Contractor: Immucor, Inc.	
Manufacturer/Contractor POC & phone number: 800-8	29-2553
Mfgr/Contractor Address: 3130 Gateway Drive, PO Box !	5625, Norcross, GA 30091
Dealer/Rep address/phone number: G. Riley, 855-466-8	267, griley@immucor.com
☐ The requested material or service represents the mi	inimum requirements of the Government.
(1) AGENCY AND CONTRACTING ACTIVITY:	Department of Veterans Affairs – NCO 2
3	222 Richmond Ave Bldg 3 Rm 103
	Batavia, NY 14020
VISN:	02
(2) NATURE AND/OR DESCRIPTION OF ACTION BEING	APPROVED:

This requirement is for red blood cell reagents which are utilized to test blood for certain illnesses/diseases prior to use in transfusions. This will be a firm-fixed price Blanket Purchase Agreement (BPA) for these laboratory testing reagents. This requirement is meant to establish a multi-year contracting vehicle for the laboratory to place orders against annually or as needed.

(3) (a) A DESCRIPTION OF THE SUPPLIES OR SERVICES REQUIRED TO MEET THE AGENCY'S NEED:

All required items for testing are on FSS contract # V797P-5944X, which currently expires June 30, 2015. These items are as follows:

Coombs Control Cells (#2226) - (26) 10 mL vials/year

Coombs Control Cells, Strong (#2224) - (66) 10 mL vials/year

Panocell 16 (#2332) - (39) 16 x 3 mL vials/year

Panoscreen I, II (#2380) - (26) 2 x 10 mL vials/year

Reference Cells A2 (#2342) - (39) 10 mL vials/year

Antibody Detection (I, II, and III), Panoscreen 2-4% (#2381) - (13) 3 x 10 mL vials/year

Coombs Complement (#7930) - (77) 3 mL vials/year

Quality Control, 2 Level (#2400) - (39) 2 x 11.5 mL vials/year

Reverse Grouping Cells (#2345) - (91) 2 x 10 mL sets/year

Per the NAC Contracting Officer, this contract will be extended and pricing updated once it is received from the

Memorandum 2011-003 December 28, 2010

contract	or prior to the expiration date. This requirement is anticipated to be a Blanket Purchase Agreement
	he FSS contract.
(b)	ESTIMATED DOLLAR VALUE:
(c)	REQUIRED DELIVERY DATE: 7/1/15 and negotiated dates thereafter during life of BPA
(4) IDE	NTIFICATION OF THE JUSTIFICATION RATIONALE (SEE FAR 8.405-6), AND IF APPLICABLE, A
	STRATION OF THE PROPOSED CONTRACTOR'S UNIQUE QUALIFICATIONS TO PROVIDE THE REQUIRED
	OR SERVICE.
	specific characteristics of the material or service that limit the availability to a sole source (unique
features,	function of the item, etc.). Describe in detail why only this suggested source can furnish the
	nents to the exclusion of other sources.
	is currently the only FSS schedule holder (V797P-5944X) producing all of the required reagents listed
	the quality and quantity levels required by the VA in VISN 2. These products are currently on a
	ry Schedule 65 under SIN 555-1 (Blood Bank). After looking through the price lists on the NAC website,
	ts that no other company distributes these specific products. Therefore, Immucor appears to be the only
	f supply for these products. Moreover, after significant discussion and analysis with the VISN 2 ry group, there are no other comparable products with the same quality and quantity levels on a VA
contract	
COTTCT GCC	
	A patent, copyright or proprietary data limits competition. The proprietary data is:
	hese are "direct replacements" parts/components for existing equipment.
	The material/service must be compatible in all aspects (form, fit and function) with existing systems
	/ installed/performing. Describe the equipment/function you have now and how the new item/service
	ordinate, connect, or interface with the existing system. nts listed above are part of a unique testing assay utilized by the laboratories throughout VISN 2.
	the VISN 2 laboratories tested a few different providers with FSS contracts to see if their new testing
	et the same quality and quantity standards as the current provider. With the exception of Immucor,
7-2-3	the other FSS vendors provide testing materials that meet the same level of quality and quantity that
	ent provider (Immucor) provides. Ultimately, there are no items that can be substituted for the
	d reagents at this time.
original o	The new work is a logical follow-on to an original Federal Supply Schedule order provided that the order was placed in accordance with the applicable Federal Supply Schedule ordering procedures. The order must not have been previously issued under sole source or limited source procedures.

Service Area Office, East Department of Veterans Affairs 323 North Shore Drive, Suite 500 Memorandum 2011-003 Pittsburgh, PA 15212 December 28, 2010 An urgent and compelling need exists, and following the ordering procedures would result in unacceptable delays. (5) DESCRIBE WHY YOU BELIEVE THE ORDER REPRESENTS THE BEST VALUE CONSISTENT WITH FAR 8.404(d) TO AID THE CONTRACTING OFFICER IN MAKING THIS BEST VALUE DETERMINATION: In accordance with FAR 8.405-6(a)(i)(B), only one source holding a FSS contract is capable of supplying these items. See above for more details. Moreover, Immucor has a strong history of positive past performance. There are currently no terminations listed in the FAPIIS database and no recorded instances of defective pricing. Additionally, Immucor's delivery system is highly efficient and therefore is able to provide these testing supplies quickly. Finally, when negotiated, the Contracting Officer for the FSS contract sought the best value for these tests. In addition to this, the Contracting Officer for this requirement will seek additional discounts if possible for this requirement. (6) DESCRIBE THE MARKET RESEARCH CONDUCTED AMONG SCHEDULE HOLDERS AND THE RESULTS OR A STATEMENT OF THE REASON MARKET RESEARCH WAS NOT CONDUCTED: These blood testing items have been used throughout VISN 2 for many years. Most recently, these supplies were purchased against the Immucor FSS contract (V797P-5944X) as a task order (VA528-15-F-0454) with deliveries through the current end date of the FSS contract (June 30, 2015). This order was written against the mandatory Schedule 65 FSS contract. Only one schedule holder under SIN 555-1 (Blood Bank) provides these testing supplies at a level of quality and quantity that is acceptable to the VISN 2 laboratories: Immucor, Inc. Additional searches were conducted to see what other companies could provide testing materials of the same quality and quantity as the current provider. As a result, the VISN 2 laboratories recently received and tested reagent supplies from other vendors listed under SIN 555-1 that appeared to provide most of the same general type of testing materials. As a result of these tests, no other company was identified as having supplies of the same quality or quantity as Immucor with the most significant concern being false positives or lack of indication with some of the newly tested reagents. Further, the most recent procurement of these testing supplies solicited and awarded in November 2015 concluded the same procurement decision. At that time, a limited source justification was approved. The market research for the award in November 2015 included contacting major medical distributors, other companies listed under FSS SIN 555-1, and a review of DLA's Medical Product

(7) ANY OTHER FACTS SUPPORTING THE JUSTIFICATI		

required for blood testing prior to transfusion use in VISN 2.

(8) A STATEMENT OF THE ACTIONS, IF ANY, THE AGENCY MAY TAKE TO REMOVE OR OVERCOME ANY BARRIERS THAT LED TO THE RESTRICTED CONSIDERATION BEFORE ANY SUBSEQUENT ACQUISITION FOR THE SUPPLIES OR SERVICES IS MADE:

<u>Database</u> (MedPDB) which showed that all VA hospitals in the nation currently procure these reagents directly from Immucor and no distributor other than Immucor was on file for these items. In sum, the market research demonstrates that only one supplier (Immucor, Inc.) has acceptable quality and quantity of testing reagents

There is no known action that will overcome this barrier other than another provider entering the market with an equal or superior product that can meet VISN 2's quality and quantity requirements. The VA will continue to

Memorandum 2011-003 December 28, 2010

monitor the market for red blood cell testing reagents that are of acceptable quality and quantity from other manufacturers and encourage competition wherever possible.

(9) <u>REQUIREMENTS CERTIFICATION:</u> I certify that the requirement outlined in this justification is a bonafide need of the Department of Veterans Affairs and that the supporting data under my cognizance, which are included in the justification, are accurate and complete to the best of my knowledge. I understand that processing of this limited sources justification restricts consideration of Federal Supply Schedule contractors to fewer than the number required by FAR Subpart 8.4.

			4/14/20:	15	
SIGNATURE		A50051	DATE	*	
		Medical Technol	ogist, COR	Lab Service-113	
NAME		TITLE		SERVICE LINE/SECTION	
Albany-Stratton VA	Medical Cente	r			
FACILITY					
(10) APPROVALS II	N ACCORDANCI	E WITH FAR 8.405	-6(h):		
a. <u>CONTRACTING</u> (complete to the be			ed): I certify t	hat the foregoing justification is accurat	e and
			4/14/2015		
CONTRACTING OFF	ICER'S SIGNATU	JRE	DATE		
	į.		NCO 2		
CONTRACTING OFF	ICER		FACILITY		
b. ONE LEVEL ABO	VE CONTRACTI	NG OFFICER: I cer belief. *This signat	tify that the for	Pregoing justification is accurate and come VISN NCM if the Contracting Officer and	
SIGNATURE			DATE		
	, NCO 2 S	Supply Branch Chie	ef		
NAME AND TITLE					
	· · · · · · · · · · · · · · · · · · ·				
SIGNATURE			DATE		
NAME AND TITLE	, NCO 2 [Division Chief			
NIABAL ARIII IIIL					

Memorandum 2011-003 December 28, 2010

c. <u>NCM</u> : I certify the justification meets required contractors to fewer than the number required	uirements for restricting consideration of Federal Supply Schedule d by FAR Subpart 8.4.
	DATE
d. <u>SAO EAST</u> : I certify the justification meets Schedule contractors to fewer than the number	s requirements for restricting consideration of the Federal Supply er required by FAR Subpart 8.4.
Director, SAO East	DATE
justification and find it to be complete and acc	\$650,000 to \$12.5 million): I have reviewed the foregoing curate to the best of my knowledge and belief and approve for a Schedule contractors to fewer than the number required by FAR
	DATE
Head of Contracting Activity (HCA)	
	val (over \$12.5 million): I have reviewed the foregoing justification best of my knowledge and belief and approve for other than full
	Date
Deputy Assistant Secretary	
Office of Acquisition and Logistics	
Senior Procurement Executive (SPE)	